Gilead, AbbVie still have plenty of hep C patients to treat; Docs, pharmacists mix up Brintellix and Brilinta;

> Next-gen hep C drugmakers Gilead ($GILD) and AbbVie ($ABBV) still have a huge treatable population, with more than 2 million untreated patients remaining in the U.S. Report

> With three products nearing biosimilar competition, Amgen ($AMGN) will be the first to defend its products in the U.S. More

> Shire ($SHPG) has picked up Foresight Biotherapeutics Inc. for $300 million in cash, gaining access to a late-stage experimental pink eye drug. Report

> China is expanding medical insurance to cover all critical illnesses for all urban and rural residents by the end of the year. More

And Finally... Lundbeck and Takeda's antidepressant Brintellix and AstraZeneca's ($AZN) anti-clotting agent Brilinta have been confused at least 50 times by doctors and pharmacists, the FDA says. More

Suggested Articles

Novartis is joining a group of drugmakers already advertising cancer treatments on TV with the launch of its Piqray campaign. 

With Johnson & Johnson battling talc and opioid lawsuits and now a Risperdal verdict, is the brand facing a decline?

Transparency in drug pricing sounds like a great idea, but a new study finds that almost none of the state laws provide real price insights.